Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NIREUS: Registrational Trial of Ridaforolimus-Eluting Stent (NIRsupreme) for Use in Coronary Artery Disease.

Trial Profile

NIREUS: Registrational Trial of Ridaforolimus-Eluting Stent (NIRsupreme) for Use in Coronary Artery Disease.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications Coronary artery disease
  • Focus Registrational; Therapeutic Use
  • Acronyms NIREUS
  • Most Recent Events

    • 21 Dec 2016 According to a Medinol media release, results from this trial presented at the opening Late Breaking Trial session of the 28th annual Transcatheter Cardiovascular Therapeutics (TCT2016) scientific symposium.
    • 17 May 2016 Results (n=302) published in a Medinol media release.
    • 17 May 2016 According to a Medinol media release, results of this trial were presented at the EuroPCR 2016 conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top